# Sapience Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sapience-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.sapiencetherapeutics.com
- Total disclosed funding: $64M
- Latest round: Series B (May 31, 2022)
- Investors on record: 6

## About

Sapience Therapeutics, Inc. focuses on developing innovative peptide therapeutics for oncology, targeting challenging cancer types through advanced treatments. Their products aim to improve patient outcomes in cancer care.Sapience Therapeutics, Inc. specializes in peptide therapeutics for cancer treatment. Founded in 2015, the company is based in the US and has not undergone any notable pivots. The firm was founded by Barry Kappel, who also serves as the CEO. Sapience has successfully completed 5 deals, with the most recent being a Series B funding round in May 2022, raising USD 41.00 mn, led by NexPoint and supported by Bristol-Myers Squibb Company, Eshelman Ventures, and Kingdon Capital Management. The total amount raised by the company to date is USD 41.00 mn, with a current valuation of USD 264.25 mn.Sapience Therapeutics specializes in the development of innovative peptide therapeutics aimed at oncology treatment. Their core product offerings include SPEARs™ (therapeutic peptides that act inside cancer cells) and SPARCs™ (therapeutic peptides that target the exterior of cancer cells). Notable products in their pipeline include lucicebtide (formerly known as ST101) and ST316, both of which are currently in Phase 2 clinical trials. These products are designed to target traditionally elusive oncogenic proteins, addressing unmet medical needs in conditions such as glioblastoma and colorectal cancer. Their client base primarily comprises healthcare providers and oncology specialists in North America and Europe, with prospects for expansion into additional global markets as their products progress through clinical trials.Sapience Therapeutics generates revenue through collaborations and partnerships in the biotechnology and pharmaceutical sectors, particularly in relation to their proprietary peptide therapeutics. Transactions typically occur within a framework of clinical trial partnerships, where healthcare institutions and research organizations may engage in agreements to evaluate the efficacy of Sapience's lead products. The pricing structure is based on contractual agreements tied to the advancement of their clinical trials and the commercialization of their products, especially the trademarked SPEARs™ and SPARCs™. These agreements involve milestone payments linked to specific development stages in addition to potential royalties from product sales following successful market entry.Sapience Therapeutics plans to utilize the USD 41.00 mn raised in their Series B funding round to accelerate their pipeline of peptide therapeutics. The company aims to launch new products, with a focus on enhancing their offerings in oncology treatment. Additionally, they are targeting expansion into new geographical markets, with specific plans to reach additional regions in North America and Europe. Their strategic initiatives are set to further their clinical trials and product development in the coming years.

## Funding rounds

- Series B, May 31, 2022, $41M — Kingdon Capital Management, Bristol-Myers Squibb Company, Eshelman Ventures, NexPoint
- Series A, Jul 12, 2016, $23M — TaiAn Technologies Corporation, Eshelman Ventures, Bristol-Myers Squibb Company, Healthlink Capital

## Investors

- TaiAn Technologies Corporation (https://capitalatlas.ai/funds/taian-technologies-corporation) — Series A
- Eshelman Ventures (https://capitalatlas.ai/funds/eshelman-ventures) — Series A, Series B
- Bristol-Myers Squibb Company — Series A, Series B
- Healthlink Capital — Series A
- Kingdon Capital Management — Series B
- NexPoint — Series B